Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
CNY 13.61
(-1.23%)
CNY 13.61
(-1.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.23 Billion CNY | -0.37% |
| 2022 | 2.24 Billion CNY | 11.03% |
| 2021 | 2.02 Billion CNY | 55.59% |
| 2020 | 1.3 Billion CNY | 24.37% |
| 2019 | 1.04 Billion CNY | 12.3% |
| 2018 | 930.92 Million CNY | 165.08% |
| 2017 | 351.19 Million CNY | 56.59% |
| 2016 | 224.26 Million CNY | 23.34% |
| 2015 | 181.83 Million CNY | -54.83% |
| 2014 | 402.54 Million CNY | 6.71% |
| 2013 | 377.24 Million CNY | -3.02% |
| 2012 | 389 Million CNY | 17.35% |
| 2011 | 331.49 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.35 Billion CNY | 0.92% |
| 2024 Q1 | 2.14 Billion CNY | -4.27% |
| 2024 Q2 | 2.32 Billion CNY | 8.73% |
| 2023 Q1 | 2.19 Billion CNY | -2.11% |
| 2023 Q4 | 2.23 Billion CNY | -7.98% |
| 2023 Q3 | 2.43 Billion CNY | 13.42% |
| 2023 Q2 | 2.14 Billion CNY | -2.49% |
| 2023 FY | 2.23 Billion CNY | -0.37% |
| 2022 Q4 | 2.24 Billion CNY | -7.3% |
| 2022 FY | 2.24 Billion CNY | 11.03% |
| 2022 Q3 | 2.42 Billion CNY | 3.98% |
| 2022 Q2 | 2.33 Billion CNY | 15.93% |
| 2022 Q1 | 2.01 Billion CNY | -0.64% |
| 2021 Q2 | 1.59 Billion CNY | -6.2% |
| 2021 FY | 2.02 Billion CNY | 55.59% |
| 2021 Q1 | 1.7 Billion CNY | 30.81% |
| 2021 Q4 | 2.02 Billion CNY | 21.14% |
| 2021 Q3 | 1.66 Billion CNY | 4.67% |
| 2020 Q1 | 1.17 Billion CNY | 12.64% |
| 2020 Q2 | 1.11 Billion CNY | -5.29% |
| 2020 Q3 | 1.09 Billion CNY | -2.03% |
| 2020 FY | 1.3 Billion CNY | 24.37% |
| 2020 Q4 | 1.3 Billion CNY | 19.0% |
| 2019 Q3 | 1.01 Billion CNY | 4.68% |
| 2019 Q1 | 991.76 Million CNY | 6.54% |
| 2019 FY | 1.04 Billion CNY | 12.3% |
| 2019 Q4 | 1.04 Billion CNY | 2.81% |
| 2019 Q2 | 971.4 Million CNY | -2.05% |
| 2018 Q2 | 705.72 Million CNY | 45.07% |
| 2018 FY | 930.92 Million CNY | 165.08% |
| 2018 Q4 | 930.92 Million CNY | 5.32% |
| 2018 Q3 | 883.88 Million CNY | 25.25% |
| 2018 Q1 | 486.48 Million CNY | 38.52% |
| 2017 Q3 | 326.86 Million CNY | 11.4% |
| 2017 Q2 | 293.41 Million CNY | 23.95% |
| 2017 Q1 | 236.72 Million CNY | 5.55% |
| 2017 FY | 351.19 Million CNY | 56.59% |
| 2017 Q4 | 351.19 Million CNY | 7.44% |
| 2016 Q4 | 224.26 Million CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 224.26 Million CNY | 23.34% |
| 2015 FY | 181.83 Million CNY | -54.83% |
| 2014 Q4 | 402.54 Million CNY | 0.0% |
| 2014 Q1 | 302.89 Million CNY | 0.0% |
| 2014 FY | 402.54 Million CNY | 6.71% |
| 2014 Q2 | 302.89 Million CNY | 0.0% |
| 2013 FY | 377.24 Million CNY | -3.02% |
| 2012 FY | 389 Million CNY | 17.35% |
| 2011 FY | 331.49 Million CNY | 0.0% |